Ipsen is a global specialty-driven biopharmaceutical group focused on innovation and Specialty Care. It develops and commercializes innovative medicines in three key therapeutic areas - Oncology, Neurosciences and Rare Diseases. Its commitment to oncology is exemplified through its growing portfolio of key therapies for prostate cancer, neuroendocrine tumors, renal cell carcinoma and pancreatic cancer. Ipsen also has a well-established Consumer Healthcare business. With total sales close to €1.909 billion in 2017, Ipsen sells more than 20 drugs in over 115 countries, with a direct commercial presence in more than 30 countries. Ipsen's R&D is focused on its innovative and differentiated technological platforms located in the heart of the leading biotechnological and life sciences hubs (Paris-Saclay, France; Oxford, UK; Cambridge, US). The Group has about 5,400 employees worldwide.
Ipsen is a global biopharmaceutical group dedicated to improving lives through innovative medicines in Oncology, Neuroscience and Rare Diseases. They also have a well-established and successful Consumer Healthcare business. They are committed to discovering new solutions for targeting debilitating diseases and improving the quality of life for patients.
Since it was founded in 1929, by Henri Beaufour, Ipsen has developed, and made available to patients, a number of products in Oncology, Neuroscience, Rare Diseases and Consumer Healthcare. Global footprint, acquisitions, partnerships, scientific collaborations and innovations: learn about the development of their group over the years.
Discover all the information relating to the leadership teams of the Ipsen Group: presentation of the executive management and composition of the Board Committees.
Their strategy is to build a global biopharma company focused on innovation and specialty care which delivers differentiated therapeutics to meet unmet patient needs. Their biotech mindset – combined with the scale and advantages of a global biopharmaceutical company – has already established them as a development and commercial powerhouse in their core focused areas, with a proven ability to bring new, life changing therapies to market.
The Ipsen Group’s medicines are used in over 115 countries across the globe. Their extensive and diversified geographic footprint allows them to meet the needs of patients at their commercial operations sites, industrial sites and R&D centers: Discover their Group’s locations on the interactive map.
Where is Ipsen Group